TDOCTeladoc Health, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−12% a year). The price bakes in little to no growth.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What TDOC's price assumes
Today's price asks for −12% free cash flow growth a year; over the last three years Teladoc Health, Inc. delivered 3.5%, less than the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 18%
Free cash flow yield · Health Information Services median 6.3%
- Growth the price implies
- −12%
Growth the price implies · The price pays for −12% free cash flow growth a year for a decade; the business has delivered +3.5% a year over the last three.
- Price / book
- 1.03
Price / book · today's price, fiscal year to Dec 31, 2025
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 1.03
- EV / EBIToperating margin −7.5%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 0.26
- Free cash flow, trailing twelve months
- $254M
- Market capitalisation
- $1.43B
- 3-year free cash flow growth
- +3.5%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #17 of 20 by RyuScore